SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy


  • Org Study ID: 18-0402
  • Secondary ID:
  • NCT ID: NCT04068896
  • NCT Alias:
  • Sponsor: NGM Biopharmaceuticals, Inc - Industry
  • Source: NGM Biopharmaceuticals, Inc

Brief Summary

Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer.

Overal Status Start Date Phase Study Type
Recruiting October 16, 2019 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)

Primary Outcome 1 - Time Frame: 19 weeks

Condition:

  • Pancreatic Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Ovarian Cancer
  • Head Neck Squamous Cell Carcinoma

Eligibility

Criteria:
Inclusion Criteria:

1. Have histologically confirmed advanced or metastatic castration-resistant prostate
cancer, bladder cancer, melanoma, non-small cell lung cancer, pancreatic cancer,
colorectal cancer, gastric cancer, esophageal cancer, ovarian cancer, and head neck
squamous cell carcinoma.

Or,

Have histologically confirmed metastatic pancreatic adenocarcinoma. Recurrent
unresectable pancreatic cancer is acceptable as long as the treatment is first-line.

2. Have not received any approved chemotherapy, except in the adjuvant setting.

Exclusion Criteria:

1. Subject was using immunosuppressive medications within 14 days before Screening with
the exception of topical (intranasal, inhaled, and local injection), systemic
(prednisone equivalent 10 mg/day or less), or as needed for hypersensitivity reactions
such as computed tomography (CT) scan premedication.

2. Subject has active infections or other serious underlying significant medical illness,
abnormal and clinically significant laboratory findings or psychiatric illness/social
situation.

3. Subject is using a pacemaker, implantable cardiac defibrillator, neurostimulator,
cochlear implants, cochlear implants, or other electronic medical equipment.

4. Subject has documented immunodeficiency or organ transplant.

5. Subject has an untreated central nervous system disease, leptomeningeal disease or
cord compression.

6. Subject has a history, or presence, of significant cardiovascular diseases; including
uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or
myocardial infarction within 6 months before randomization, congestive heart failure >
New York Heart Association Class II, severe peripheral vascular disease, corrected QT
(QTc) prolongation >470 msec, clinically significant pericardial effusion.

7. Subject has a history or presence of documented inflammatory bowel disease.

8. Subject is known to be positive for human immunodeficiency virus infection.

-
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: NGM Study Director

Role: Study Director

Affiliation: NGM Biopharmaceuticals, Inc

Overall Contact

Name: Kathy Kim

Phone: 650-243-5555

Email: kkim@ngmbio.com

Locations

Facility Status Contact
NGM Clinical Study Site
Los Angeles, California 90048
United States
Not yet recruiting NGM Site 122

NGM Clinical Study Site
Los Angeles, California 90084
United States
Recruiting NGM Site 105

NGM Clinical Study Site
Sacramento, California 98517
United States
Recruiting NGM Site 108

NGM Clinical Study Site
San Diego, California 92123
United States
Not yet recruiting NGM Site 113

NGM Clinical Study Site
Santa Monica, California 90404
United States
Not yet recruiting NGM Site 102

NGM Clinical Study Site
Aurora, Colorado 80045
United States
Recruiting NGM Site 110

NGM Clinical Study Site
Washington, District of Columbia 20007
United States
Not yet recruiting NGM Site 117

NGM Clinical Study Site
Miami, Florida 33136
United States
Not yet recruiting NGM Site 120

NGM Clinical Study Site
Chicago, Illinois 60611
United States
Not yet recruiting NGM Site 119

NGM Clinical Study Site
Lewiston, Maine 04240
United States
Recruiting NGM Site 106

NGM Clinical Study Site
Baltimore, Maryland 21201
United States
Recruiting NGM Site 103

NGM Clinical Study Site
Boston, Massachusetts 02118
United States
Recruiting NGM Site 115

NGM Clinical Study Site
Detroit, Michigan 48201
United States
Recruiting NGM Site 111

NGM Clinical Study Site
Lake Success, New York 11042
United States
Not yet recruiting NGM Site 123

NGM Clinical Study Site
Cincinnati, Ohio 45219
United States
Recruiting NGM Site 104

NGM Clinical Study Site
Portland, Oregon 97239
United States
Not yet recruiting NGM Site 125

NGM Clinical Study Site
Philadelphia, Pennsylvania 19111
United States
Not yet recruiting NGM Site 124

NGM Clinical Study Site
Charleston, South Carolina 29425
United States
Not yet recruiting NGM Site 101

NGM Clinical Study Site
Greenville, South Carolina 29605
United States
Recruiting NGM Site 116

NGM Clinical Study Site
Nashville, Tennessee 37203
United States
Recruiting NGM Site 118

NGM Clinical Study Site
Dallas, Texas 75390
United States
Not yet recruiting NGM Site 127

NGM Clinical Study Site
Houston, Texas 77030
United States
Not yet recruiting NGM Site 107

NGM Clinical Study Site
Houston, Texas 77030
United States
Not yet recruiting NGM Site 126

NGM Clinical Study Site
Seattle, Washington 98101
United States
Not yet recruiting NGM Site 109

NGM Clinical Study Site
Milwaukee, Wisconsin 53226
United States
Recruiting NGM Site 112